Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
National Institutes of Health
Award
USD 0–1M ≈ €0–€920K
Closing date
726 days left · May 07, 2028
Location
Global
For
Orgs
About this opportunity
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of Alzheimer's Disease and related dementias. The program seeks to advance translational bioinformatics and experimental approaches to identify promising therapeutic candidates through preclinical validation.
Who can apply
Applicant Types
organization
Organization Types
nonprofit, academic, for profit, government, tribal
Project Locations
🇺🇸 United States
Region
United States
How to apply
Stages
- 1 single_stage
Required documents
research_proposal · budget
Restrictions
- no_concurrent_funding
Post-award obligations
- final_report
- acknowledge_funder